C4 is building on the knowledge with synthetic chemical compounds. Founded by Jay Bradner, Ken Anderson, Marc Cohen, and Nathanael Gray in 2015, C4 Therapeutics is backed by investors that include 3E Bioventures, Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Cobro Ventures, Commodore Capital, HBM Healthcare Investments AG, Janus Henderson Investors, Lightchain, Logos Capital, Mizuho Securities Principal Investment, Nextech Invest, Perceptive Advisors, RA Capital Management, RTW Investments LLC, Sphera Funds Management, T. Rowe Price, Taiwania Capital, and Yonjin Venture and is headquartered in Cambridge.